Pfizer skillfully extended Viagra’s patent life through several key actions. They filed numerous patent applications covering different aspects of the drug, including its manufacturing process and specific formulations, thus creating a complex patent portfolio.
Patent term adjustments were utilized, adding time to the original patent based on regulatory delays during the approval process. This legally extended their exclusive rights.
Strategic litigation played a significant role. Pfizer aggressively defended its patents against generic competition, engaging in lengthy legal battles to delay market entry by generic manufacturers. This involved presenting data showing their patents covered unique aspects not addressed by generic alternatives.
Finally, Pfizer successfully negotiated licensing agreements with some generic manufacturers, providing a controlled and potentially more profitable exit strategy for themselves instead of facing immediate full generic competition.
